What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Year 2025 Títol Complet Servicio de genotipado destinado a la Unidad de Cáncer Hereditario de la Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca (VHIR), destinado al proyecto titulado “PRISMA-II: Estratificación del riesgo de cáncer de mama/ovario mediante incorporación del polygenic risk score. Validación en portadoras, cohorte prospectiva, y viabilidad de la secuenciación de genoma” (PI23/01047) financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea Expedient SERVICIO DE ARRAYS PRS (FIS PI23/01047) Codi 24984627 Data publicació Thu, 5 Jun 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1. PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML. INSTRUCCIONS PER EMPLENAR EL DEUC ACORD DE NECESSITAT RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE NÚM. 3 REQUERIMIENTO Y PROPUESTA DE ADJUDICACIÓN PROVISIONAL ACUERDO DE ADJUDICACIÓN Professionals Laura Roman Pons Professionals Éric Suárez Carrillo A phase I//II trial of ABTL0812 in children with relapsed//refractory neuroblastoma and other solid tumour Contact Protocol code: ETNA EudraCT code: No aplica Pathology: Tumors Principal investigator: Moreno Martín-Retortillo, Lucas Research group: Càncer i malalties hematològiques infantils Service: Oncohematologia Pediàtrica Phase: Fase I Recruiting: Open Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4//6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2 Negative (IHC 0, 1+, 2+// ISH non amplified) Advanced Breast Cancer (EvoPAR-Breast01) Contact Protocol code: D9722C00001 - EvoPAR-Breast01 EudraCT code: No aplica Pathology: Tumors Principal investigator: Pimentel , Isabel Service: Oncologia Phase: Fase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio aleatorizado, doble ciego, controlado con placebo, de dosis únicaascendente, Fase 1a // 1b, multicéntrico, en participantes sanos y participantes con poliquistosisrenal autosómica dominante para evaluar la seguridad, tolerabilidad, farmacocinética yfarmacodinamia de GSK4771261. Contact Protocol code: 221362 EudraCT code: No aplica Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Bestard Matamoros, Oriol Research group: Nefrologia i trasplantament renal Service: Nefrologia Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3, aleatorizado, doble ciego, controlado conplacebo y multicéntrico para investigar la eficacia, la seguridad y la tolerabilidad deLP352 en el tratamiento de las crisis convulsivas en niños y adultos con síndrome deDravet Contact Protocol code: LP352-302 EudraCT code: No aplica Pathology: Malalties del sistema nerviós Principal investigator: Toledo Argany, Manuel Research group: Grup de recerca de l'estat epilèptic i crisis agudes Service: Neurologia Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio fase 3 multicéntrico, aleatorizado, doble ciego ycontrolado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113para el tratamiento de pacientes con artritis psoriásica activa sin tratamientobiológico previo. Contact Protocol code: 77242113PSA3001 EudraCT code: No aplica Pathology: Malalties de la pell i del teixit subcutani Principal investigator: Erra Duran, Maria Alba Research group: Reumatologia Service: Reumatologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY Contact Protocol code: AIS-D08 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Agraz Pamplona, Irene Research group: Nephrology and kidney transplantation Service: Nephrology Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase III, aleatorizado, con doble enmascaramiento ycomparativo con placebo con un periodo de prolongación sin enmascaramiento paraevaluar la eficacia y la seguridad de telitacicept en pacientes con miastenia gravegeneralizada Contact Protocol code: RC18G006 EudraCT code: No aplica Pathology: Nervous system diseases Principal investigator: Juntas Morales, Raul Research group: Sistema nerviós perifèric Service: Neurology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de extensión abierto de Olezarsen (ISIS 678354)administrado por vía subcutánea en pacientes con hipertrigliceridemia grave (SHTG). Contact Protocol code: ISIS 678354-CS15 EudraCT code: No aplica Pathology: Malalties endocrines, nutricionals i metabòliques Principal investigator: Ortiz Zúñiga, Angel Michael Research group: Diabetis i metabolisme Service: Endocrinologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Multicentre, Randomised, Double-Blind, ParallelGroup, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety ofBenralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting ß2-Agonist Contact Protocol code: D3250C00101 EudraCT code: No aplica Pathology: Malalties del sistema respiratori Principal investigator: Muñoz Gall, Fco. Javier Research group: Pneumologia Service: Pneumologia Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. ESTUDIO INTERVENCIONAL DE EFICACIA YSEGURIDAD, FASE III, ALEATORIZADO, DOBLE CIEGO,CONTROLADO CON PLACEBO, SEGUIDO DE UN PERIODOABIERTO, PARA INVESTIGAR RIMEGEPANT EN LAPREVENCIÓN DE LA MIGRAÑA EN ADOLESCENTES DE ENTRE12 Y MENOS DE 18 AÑOS DE EDAD CON MIGRAÑA CRÓNICA Contact Protocol code: C4951013 EudraCT code: No aplica Pathology: Nervous system diseases Principal investigator: Pozo Rosich, Patricia Research group: Cefalea i dolor neurològic Service: Neurology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Single-arm open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 3000202 in adult patients with selected type 1 interferonopathies. Contact Protocol code: 1509-0003 EudraCT code: _ Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Lopez Corbeto, Mireia Research group: Rheumatology Service: Rheumatology Phase: Phase I Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A phase II study to evaluate DNTH103 in adults with multifocal motor neuropathy (MOMENTUM) Contact Protocol code: DNTH103-MMN-201 EudraCT code: _ Pathology: Nervous system diseases Principal investigator: Juntas Morales, Raul Research group: Peripheral Nervous System Service: Neurology Phase: Fase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase II, aleatorizado, doble ciego y controlado con placebosobre el uso de ensifentrina en pacientes con bronquiectasia no asociada a fibrosisquística. Contact Protocol code: RPL554-NCFB-220 EudraCT code: No aplica Pathology: Tumors Principal investigator: Polverino , Eva Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo de fase II, aleatorizado y abierto para comparar el tratamiento endocrino neoadyuvante en combinación con trastuzumab y pertuzumab con o sin el inhibidor de la PI3K inavolisib en pacientes con cáncer de mama precoz RH+//HER2+ con mutación de PIK3CA – GeparPiPPa Contact Protocol code: GBG 105 EudraCT code: No aplica Pathology: Tumors Principal investigator: Escriva de Romaní Muñoz, Santiago Ignacio Service: Oncology Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de maralixibat en el tratamiento de participantes con prurito colestásico Contact Protocol code: MRX-802 EudraCT code: No aplica Pathology: Malalties del sistema digestiu Principal investigator: Quintero Bernabeu, Jesús Research group: Cirurgia general Service: Pediatria General i Especialitats Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Contact Protocol code: 20297A EudraCT code: No aplica Pathology: Nervous system diseases Principal investigator: Pozo Rosich, Patricia Research group: Headache and Neurological Pain Service: Neurology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3, multinacional, aleatorizado, doble ciego ycontrolado con placebo para evaluar la eficacia y la seguridad del treprostinilo inhalado enpacientes con fibrosis pulmonar progresiva (TETON-PPF) Contact Protocol code: RIN-PF-305 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Villar Gomez, Ana Research group: Pneumology Service: Pneumology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Pagination First page « Previous page ‹ … Page 308 Page 309 Current page 310 Page 311 Page 312 … Next page › Last page »
Year 2025 Títol Complet Servicio de genotipado destinado a la Unidad de Cáncer Hereditario de la Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca (VHIR), destinado al proyecto titulado “PRISMA-II: Estratificación del riesgo de cáncer de mama/ovario mediante incorporación del polygenic risk score. Validación en portadoras, cohorte prospectiva, y viabilidad de la secuenciación de genoma” (PI23/01047) financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea Expedient SERVICIO DE ARRAYS PRS (FIS PI23/01047) Codi 24984627 Data publicació Thu, 5 Jun 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1. PCAP (word) PLEC DE PRESCRIPCIONS TÈCNIQUES PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML. INSTRUCCIONS PER EMPLENAR EL DEUC ACORD DE NECESSITAT RESOLUCIÓ D'APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ DE LA MESA DE CONTRACTACIÓ INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE NÚM. 3 REQUERIMIENTO Y PROPUESTA DE ADJUDICACIÓN PROVISIONAL ACUERDO DE ADJUDICACIÓN
